Alpha Tau Medical Ltd ((DRTS)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alpha Tau Medical Ltd (DRTS) is conducting a clinical study titled ‘A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer.’ The study aims to evaluate the safety and efficacy of Alpha DaRT combined with chemotherapy in treating pancreatic cancer. The primary focus is on safety, assessing adverse events, while secondary objectives include evaluating efficacy through survival rates and pain control.
The intervention being tested is the Diffusing Alpha Radiation Emitters Therapy (DaRT), a device designed to deliver targeted radiation therapy directly into tumors. This approach aims to enhance the effectiveness of chemotherapy in treating pancreatic cancer.
The study is interventional, non-randomized, and follows a parallel assignment model with no masking. It involves 30 participants divided into two cohorts, focusing on treatment as the primary purpose.
The study began on November 18, 2024, with an estimated primary completion date yet to be announced. The latest update was submitted on August 13, 2025, indicating ongoing recruitment.
This study update could influence Alpha Tau Medical’s stock performance positively, as successful outcomes may enhance investor confidence. The innovative approach may set the company apart in the competitive oncology treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.